secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001628280-24-044318
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q3 revenue $182.5M (+48% YoY); guides FY2024 to $675-700M; positive GRADIENT results
--------------------------------------------------------------------------------

- Q3 revenue $182.5M (+48% YoY); diluted EPS $0.41 vs $0.28; net income $47.2M.
- FY2024 revenue guidance raised to $675-700M from $640-670M; strong Korlym prescriber and patient growth.
- Cash and investments $547.6M; repurchased 870K shares for $23.4M in Q3.
- Phase 3 GRADIENT in Cushing's syndrome: significant improvements in BP, glucose, weight vs placebo; no hypokalemia or endometrial hypertrophy.
- NDA for relacorilant in Cushing's to be submitted this quarter; ROSELLA (ovarian cancer) and DAZALS (ALS) data expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024044318/0001628280-24-044318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024044318/cort-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-044318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer